PRVB News and Press, Provention Bio Inc. From 08/05/21

Provention Bio (NASDAQ:PRVB): Q2 GAAP EPS of -$0.46 beats by $0.06. Cash and cash equivalents and marketable securities of $176.4 million. Press Release For further details see: Provention Bio EPS beats by $0.06

Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire RED BANK, N.J. , Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-me...

It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab. I advised investors to avoid the stock due to an over-exuberance in potential for the At-Risk application of teplizumab. Shares have fallen ~60% since then, an...

Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021 PR Newswire RED BANK, N.J. , July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-media...

Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M. We believe ALT's NASH and obesity pipeline drives most of its value. The recent sell-off offers an attracti...

Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%. For further details see: NRXP, PDD, ACOR and IPA among after-hours movers

Sometimes the market overreacts to a negative development. Shares of Provention Bio (NASDAQ: PRVB) recently plunged after the FDA issued a Complete Response Letter for its diabetes drug teplizumab. In this Motley Fool Live video recorded on July 7 , Motley Fool contribu...

Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals Designation is the first step in a new MHRA initiative to accelerate the development and access to innovative medicines in the UK post-Brex...

Shares of Provention Bio (NASDAQ: PRVB) , a clinical-stage biopharmaceutical company, were beaten down 25.2% as of 12:40 p.m. EDT on Tuesday. Investors are responding to a Complete Response Letter that the company received from the Food and Drug Administration instead of an approval...

Gainers: Orbsat (OSAT) +86%.BSQUARE (BSQR) +71%.PFSweb (PFSW) +36%.Advaxis (ADXS) +35%.Powerbridge Technologies (PBTS) +34%.Bridgeline Digital (BLIN) +31%.Sequential Brands Group (SQBG) +24%.GasLog Partners (GLOP) +24%.BioHiTech Global (BHTG) +20%.Data Storage (DTST) +19%.Losers: Pop Culture ...